Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation

Jeffrey A. Smith, Celeste E. Poteet-Smith, Yaming Xu, Timothy M. Errington, Sidney Hecht, Deborah A. Lannigan

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

p90 ribosomal S6 kinase (RSK) is an important downstream effector of mitogen-activated protein kinase, but its biological functions are not well understood. We have now identified the first small-molecule, RSK-specific inhibitor, which we isolated from the tropical plant Forsteronia refracta. We have named this novel inhibitor SL0101. SL0101 shows remarkable specificity for RSK. The major determinant of SL0101-binding specificity is the unique ATP-interacting sequence in the amino-terminal kinase domain of RSK. SL0101 inhibits proliferation of the human breast cancer cell line MCF-7, producing a cell cycle block in G1 phase with an efficacy paralleling its ability to inhibit RSK in intact cells. RNA interference of RSK expression confirmed that RSK regulates MCF-7 proliferation. Interestingly, SL0101 does not alter proliferation of a normal human breast cell line MCF-10A, although SL0101 inhibits RSK in these cells. We show that RSK is overexpressed in ∼50% of human breast cancer tissue samples, suggesting that regulation of RSK has been compromised. Thus, we show that RSK has an unexpected role in proliferation of transformed cells and may be a useful new target for chemotherapeutic agents. SL0101 will provide a powerful new tool to dissect the molecular functions of RSK in cancer cells.

Original languageEnglish (US)
Pages (from-to)1027-1034
Number of pages8
JournalCancer Research
Volume65
Issue number3
StatePublished - Feb 1 2005
Externally publishedYes

Fingerprint

90-kDa Ribosomal Protein S6 Kinases
Ribosomal Protein S6 Kinases
Cell Proliferation
Neoplasms
Breast Neoplasms
Cell Line
G1 Phase
RNA Interference
SL0101
Mitogen-Activated Protein Kinases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. / Smith, Jeffrey A.; Poteet-Smith, Celeste E.; Xu, Yaming; Errington, Timothy M.; Hecht, Sidney; Lannigan, Deborah A.

In: Cancer Research, Vol. 65, No. 3, 01.02.2005, p. 1027-1034.

Research output: Contribution to journalArticle

Smith, Jeffrey A. ; Poteet-Smith, Celeste E. ; Xu, Yaming ; Errington, Timothy M. ; Hecht, Sidney ; Lannigan, Deborah A. / Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. In: Cancer Research. 2005 ; Vol. 65, No. 3. pp. 1027-1034.
@article{df2ae2b4eadf420fb1bad87133748d8e,
title = "Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation",
abstract = "p90 ribosomal S6 kinase (RSK) is an important downstream effector of mitogen-activated protein kinase, but its biological functions are not well understood. We have now identified the first small-molecule, RSK-specific inhibitor, which we isolated from the tropical plant Forsteronia refracta. We have named this novel inhibitor SL0101. SL0101 shows remarkable specificity for RSK. The major determinant of SL0101-binding specificity is the unique ATP-interacting sequence in the amino-terminal kinase domain of RSK. SL0101 inhibits proliferation of the human breast cancer cell line MCF-7, producing a cell cycle block in G1 phase with an efficacy paralleling its ability to inhibit RSK in intact cells. RNA interference of RSK expression confirmed that RSK regulates MCF-7 proliferation. Interestingly, SL0101 does not alter proliferation of a normal human breast cell line MCF-10A, although SL0101 inhibits RSK in these cells. We show that RSK is overexpressed in ∼50{\%} of human breast cancer tissue samples, suggesting that regulation of RSK has been compromised. Thus, we show that RSK has an unexpected role in proliferation of transformed cells and may be a useful new target for chemotherapeutic agents. SL0101 will provide a powerful new tool to dissect the molecular functions of RSK in cancer cells.",
author = "Smith, {Jeffrey A.} and Poteet-Smith, {Celeste E.} and Yaming Xu and Errington, {Timothy M.} and Sidney Hecht and Lannigan, {Deborah A.}",
year = "2005",
month = "2",
day = "1",
language = "English (US)",
volume = "65",
pages = "1027--1034",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation

AU - Smith, Jeffrey A.

AU - Poteet-Smith, Celeste E.

AU - Xu, Yaming

AU - Errington, Timothy M.

AU - Hecht, Sidney

AU - Lannigan, Deborah A.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - p90 ribosomal S6 kinase (RSK) is an important downstream effector of mitogen-activated protein kinase, but its biological functions are not well understood. We have now identified the first small-molecule, RSK-specific inhibitor, which we isolated from the tropical plant Forsteronia refracta. We have named this novel inhibitor SL0101. SL0101 shows remarkable specificity for RSK. The major determinant of SL0101-binding specificity is the unique ATP-interacting sequence in the amino-terminal kinase domain of RSK. SL0101 inhibits proliferation of the human breast cancer cell line MCF-7, producing a cell cycle block in G1 phase with an efficacy paralleling its ability to inhibit RSK in intact cells. RNA interference of RSK expression confirmed that RSK regulates MCF-7 proliferation. Interestingly, SL0101 does not alter proliferation of a normal human breast cell line MCF-10A, although SL0101 inhibits RSK in these cells. We show that RSK is overexpressed in ∼50% of human breast cancer tissue samples, suggesting that regulation of RSK has been compromised. Thus, we show that RSK has an unexpected role in proliferation of transformed cells and may be a useful new target for chemotherapeutic agents. SL0101 will provide a powerful new tool to dissect the molecular functions of RSK in cancer cells.

AB - p90 ribosomal S6 kinase (RSK) is an important downstream effector of mitogen-activated protein kinase, but its biological functions are not well understood. We have now identified the first small-molecule, RSK-specific inhibitor, which we isolated from the tropical plant Forsteronia refracta. We have named this novel inhibitor SL0101. SL0101 shows remarkable specificity for RSK. The major determinant of SL0101-binding specificity is the unique ATP-interacting sequence in the amino-terminal kinase domain of RSK. SL0101 inhibits proliferation of the human breast cancer cell line MCF-7, producing a cell cycle block in G1 phase with an efficacy paralleling its ability to inhibit RSK in intact cells. RNA interference of RSK expression confirmed that RSK regulates MCF-7 proliferation. Interestingly, SL0101 does not alter proliferation of a normal human breast cell line MCF-10A, although SL0101 inhibits RSK in these cells. We show that RSK is overexpressed in ∼50% of human breast cancer tissue samples, suggesting that regulation of RSK has been compromised. Thus, we show that RSK has an unexpected role in proliferation of transformed cells and may be a useful new target for chemotherapeutic agents. SL0101 will provide a powerful new tool to dissect the molecular functions of RSK in cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=13444270324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444270324&partnerID=8YFLogxK

M3 - Article

C2 - 15705904

AN - SCOPUS:13444270324

VL - 65

SP - 1027

EP - 1034

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -